NCT02503423 2026-03-20
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT04362007 2026-02-25
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn